Individual Tumor Profiling
Has Tumor Molecular Profiling Enabled More Effective and Less Toxic Cancer Treatment?
Top 10 Under 40
Up-and-Coming Stars Shine in Biopharma Research and Business
Podcast: FDA’s New Commissioner Hits the Ground Running
Scott Gottlieb, M.D., Commits to Speeding Up Drug Reviews, and Maintaining Safety and Efficacy
Liquid Biopsies Remain Wait and See for Some Clinicians
Circulating Biomarker Assays Promise to Refresh Cancer Profiling and Monitoring Practices
James B. Altman
James B. Altman is a member of the law firm of Miller & Chevalier Chartered. He serves as the coordinator for the firm’s Section 337 practice group, has represented clients in more than 20 Section 337 cases, and is the president of the ITC Trial Lawyers Association.